Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "ED"

9938 News Found

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
News | September 23, 2025

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent


Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
News | September 22, 2025

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada


Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain
Digitisation | September 21, 2025

Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain

The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem


AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
Clinical Trials | September 18, 2025

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo


Novo Nordisk’s Wegovy delivered 16.6% weight loss
News | September 18, 2025

Novo Nordisk’s Wegovy delivered 16.6% weight loss

Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight


Bayer inaugurates new phytomedicines lab facility
News | September 18, 2025

Bayer inaugurates new phytomedicines lab facility

The lab will facilitate the development of herbal and natural-based solutions


Enveric clears FDA feedback milestone, prepares IND submission for EB-003
Clinical Trials | September 17, 2025

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026


Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
News | September 16, 2025

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke